A clinical trial to study the effects of two drugs Unani Herbal Formula and Sharbat e Banafsha in Waram Tajawif Al Anf Muzmin

COMPARATIVE EFFICACY OF A POLYHERBAL UNANI FORMULATION AND SHARBAT-E-BANAFSHA IN WARAM TAJAWIF AL-ANF MUZMIN (CHRONIC RHINOSINUSITIS): A RANDOMIZED CLINICAL STUDY - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/12/098843

Enrollment

Registered

2025-12-10

Start date

Unknown

Completion date

Unknown

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J329- Chronic sinusitis, unspecified

Interventions

Intervention1: Polyherbal Unani formulation: Polyherbal Unani formulation will be administered orally at a dose of 50 mL twice daily for a period of 6 weeks. Control Intervention1: Sharbat e Banafsha:

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients of either gender and in age group of 20 to 50 years. 2.Duration of the disease more than 12 week. 3.Positive X ray PNS finding (Thickened mucosal lining;opacity of sinus). 4.Patient having at least two out of four cardinal symptoms (example facial pain or pressure, hyposmia or anosmia,nasal obstruction and nasal discharge) for at least 12 consecutive weeks. 5.Those who give written informed consent and comply with the study protocol.

Exclusion criteria

Exclusion criteria: 1.Patients with any congenital or acquired structural abnormalities such as nasal dermoid cysts, deviated nasal septum, atrophic rhinitis, hypertrophied turbinates, adenoidal enlargement or presence of foreign bodies. 2.Pregnant or breastfeeding women. 3.Patients diagnosed with systemic conditions like hypertension, diabetes mellitus, cancer or disorders of the liver or kidneys. 4.Individuals unwilling or unable to comply with the full course of treatment and scheduled follow-ups during the study period. 5.Patients who have received systemic corticosteroids within 4 weeks systemic or topical antibiotics within 2 weeks, intranasal corticosteroids within 2 weeks, antihistamines within 7 days or nasal decongestants within 72 hours prior to enrolment will be excluded from the study.

Design outcomes

Primary

Measure	Time frame
Absolute Eosinophil Count (AEC). Visual Analogue Scale (VAS).Timepoint: 6 weeks	—

Secondary

Measure	Time frame
SNOT-22 questionnaire for quality of life. X RAY (PNS) Water s ViewTimepoint: 6 weeks	—

Countries

India

Contacts

Public ContactTasneem Fatima

State Unani Medical College and Hospital

asifhussainusmani@gmail.com7905831926

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026